Overview
Akili Interactive is a pioneer in the Digital Therapeutics (DTx) sector, specifically known for developing the Selective Stimulus Management engine (SSME). Their flagship product, EndeavorRx, is the first FDA-cleared video game treatment for ADHD. By 2026, Akili has shifted its architecture toward a unified AI-driven personalization layer that adapts gameplay mechanics in real-time to match the user's specific cognitive profile. The technology operates on the principle of neuroplasticity, using targeted sensory stimuli and motor challenges to strengthen neural networks associated with attention and focus. Following its acquisition and transition into a private entity under Virtual Therapeutics, the company has expanded its technical stack to include larger-scale data analytics for longitudinal cognitive monitoring. Their platform utilizes complex closed-loop algorithms that function similarly to a drug's dose-response curve, adjusting difficulty levels based on millisecond-level response times. This positioning makes them a leader in the intersection of gaming and clinical neuroscience, targeting pediatric and adult populations with non-pharmacological interventions.